At fecal hemoglobin cutoff of 17 \u00b5g\/g, sensitivity and PPV were 39 percent and specificity and NPV were 93 percent<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Nov. 7, 2023 (HealthDay News) — Individuals in the upper range of fecal immunochemical test (FIT)-negative screening have an increased risk for advanced neoplasia (AN), according to a research letter published online Nov. 7 in the Annals of Internal Medicine<\/em>.<\/p>\n Tobias Niedermaier, Ph.D., from the German Cancer Research Center in Heidelberg, and colleagues provided a dose-response analysis of the association between fecal hemoglobin concentrations and the presence of AN (colorectal cancer or advanced adenoma) in an ongoing study involving participants of screening colonoscopy in Germany. A quantitative FIT was performed before screening colonoscopy. Data were included for 7,398 participants; 90.0 percent had fecal hemoglobin concentrations below the recommended FIT cutoff (17 \u00c2\u00b5g\/g).<\/p>\n The researchers found that 41 and 81 percent of all participants had hemoglobin concentrations <1.7 and <8 \u00c2\u00b5g\/g feces, respectively. There was an increase observed in the prevalence of AN, from 6 percent among those with hemoglobin concentrations <1.7 \u00c2\u00b5g\/g to 22 percent in the highest group of participants with FIT-negative results and up to 51 percent for those with FIT-positive results. Positivity was 9.9 percent at a FIT cutoff of 17 \u00c2\u00b5g\/g; sensitivity and positive predictive value for AN detection were 39 percent, while specificity and negative predictive value were 93 percent.<\/p>\n “Those in the upper range of negative FIT values are at higher risk for colorectal cancer than those in the lower range,” the authors write. “Despite increased complexity, this suggests a benefit from personalized screening intervals.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n